Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the benzenesulfonamide class. It is an experimental compound that acts as a potent inhibitor of carbonic anhydrase enzymes. The compound has demonstrated high affinity for carbonic anhydrase II (Ki = 21 nM), suggesting its mechanism involves inhibition of this enzyme. Carbonic anhydrases are involved in the reversible hydration of carbon dioxide and play roles in pH regulation and fluid balance. This molecule has not been approved for clinical use and is primarily used in research settings to study enzyme inhibition[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-N-(4-sulfamoylphenyl-ethyl)-2,4,6-trimethylpyridinium.